Page 79 - Read Online

Cheung et al. Hepatorenal syndrome before liver transplantation

Conflicts of interest 17. Garcia-Martinez R, Caraceni P, Bernardi M, Gines P, Arroyo V, Jalan
There are no conflicts of interest. R. Albumin: pathophysiologic basis of its role in the treatment of
cirrhosis and its complications. Hepatology 2013;58:1836-46.
Patient consent 18. Boyer TD, Sanyal AJ, Wong F, Frederick RT, Lake JR, O’Leary JG,
Ganger D, Jamil K, Pappas SC; REVERSE Study Investigators.
There is no patient involved. Terlipressin plus albumin is more effective than albumin alone in
improving renal function in patients with cirrhosis and hepatorenal
Ethics approval syndrome type 1. Gastroenterology 2016;150:1579-89.e2.
This review paper is waived for ethics approval. 19. Salerno F, Navickis RJ, Wilkes MM. Albumin treatment regimen for
type 1 hepatorenal syndrome: a dose-response meta-analysis. BMC
REFERENCES Gastroenterol 2015;15:167.
20. Cort JH, Albrecht I, Novakova J, Mulder JL, Jost K. Regional and
systemic haemodynamic effects of some vasopressins: structural
1. Erly B, Carey WD, Kapoor B, McKinney JM, Tam M, Wang W. features of the hormone which prolong activity. Eur J Clin Invest
Hepatorenal syndrome: a review of pathophysiology and current 1975;5:165-75.
treatment options. Semin Intervent Radiol 2015;32:445-54.
2. Baraldi O, Valentini C, Donati G, Comai G, Cuna V, Capelli I, 21. Moller S, Hansen EF, Becker U, Brinch K, Henriksen JH, Bendtsen
F. Central and systemic haemodynamic effects of terlipressin in portal
Angelini ML, Moretti MI, Angeletti A, Piscaglia F, La Manna G.
Hepatorenal syndrome: update on diagnosis and treatment. World J hypertensive patients. Liver 2000;20:51-9.
Nephrol 2015;4:511-20. 22. Barbano B, Sardo L, Gigante A, Gasperini ML, Liberatori M, Giraldi
3. Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. GD, Lacanna A, Amoroso A, Cianci R. Pathophysiology, diagnosis
Lancet 2003;29:1819-27. and clinical management of hepatorenal syndrome: from classic to
4. Pillebout E. Hepatorenal syndrome. Nephrol Ther 2014;10:61-8. new drugs. Curr Vasc Pharmacol 2014;12:125-35.
5. Arroyo V, Gines P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, 23. Gluud LL, Christensen K, Christensen E, Krag A. Systematic
Reynolds TB, Ring-Larsen H, Scholmerich J. Definition and review of randomized trials on vasoconstrictor drugs for hepatorenal
diagnostic criteria of refractory ascites and hepatorenal syndrome in syndrome. Hepatology 2010;51:576-84.
cirrhosis. International Ascites Club. Hepatology 1996;23:164-76. 24. Cavallin M, Piano S, Romano A, Fasolato S, Frigo AC, Benetti G,
6. Bittencourt PL, Farias AQ, Terra C. Renal failure in cirrhosis: Gola E, Morando F, Stanco M, Rosi S, Sticca A, Cillo U, Angeli
emerging concepts. World J Hepatol 2015;7:2336-43. P. Terlipressin given by continuous intravenous infusion versus
7. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, intravenous boluses in the treatment of hepatorenal syndrome: a
prevention and treatment of hepatorenal syndrome in cirrhosis. Gut randomized controlled study. Hepatology 2016;63:983-92.
2007;56:1310-8. 25. Velez JC, Nietert PJ. Therapeutic response to vasoconstrictors in
8. Angeli P, Morando F. Optimal management of hepatorenal syndrome hepatorenal syndrome parallels increase in mean arterial pressure: a
in patients with cirrhosis. Hepat Med 2010;2:87-98. pooled analysis of clinical trials. Am J Kidney Dis 2011;58:928-38.
9. Rodriguez E, Henrique Pereira G, Sola E, Elia C, Barreto R, Pose E, 26. Duvoux C, Zanditenas D, Hezode C, Chauvat A, Monin JL, Roudot-
Colmenero J, Fernandez J, Navasa M, Arroyo V, Gines P. Treatment Thoraval F, Mallat A, Dhumeaux D. Effects of noradrenalin and
of type 2 hepatorenal syndrome in patients awaiting transplantation: albumin in patients with type I hepatorenal syndrome: a pilot study.
effects on kidney function and transplantation outcomes. Liver Hepatology 2002;36:374-80.
Transpl 2015;21:1347-54. 27. Nassar Junior AP, Farias AQ, D’ Albuquerque LA, Carrilho FJ,
10. Angeli P, Gines P, Wong F, Bernardi M, Boyer TD, Gerbes A, Moreau Malbouisson LM. Terlipressin versus norepinephrine in the treatment
R, Jalan R, Sarin SK, Piano S, Moore K, Lee SS, Durand F, Salerno of hepatorenal syndrome: a systematic review and meta-analysis.
F, Caraceni P, Kim WR, Arroyo V, Garcia-Tsao G; International PLoS One 2014;9:e107466.
Club of Ascites. Diagnosis and management of acute kidney injury 28. Skagen C, Einstein M, Lucey MR, Said A. Combination treatment
in patients with cirrhosis: revised consensus recommendations of the with octreotide, midodrine, and albumin improves survival in patients
International Club of Ascites. Gut 2015;64:531-7. with type 1 and type 2 hepatorenal syndrome. J Clin Gastroenterol
11. Boyer TD, Sanyal AJ, Garcia-Tsao G, Blei A, Carl D, Bexon AS, Teuber 2009;43:680-5.
P, Terlipressin Study Group. Predictors of response to terlipressin plus 29. Siramolpiwat S. Transjugular intrahepatic portosystemic shunts and
albumin in hepatorenal syndrome (HRS) type 1: relationship of serum portal hypertension-related complications. World J Gastroenterol
creatinine to hemodynamics. J Hepatol 2011;55:315-21. 2014;20:16996-7010.
12. Moller S, Krag A, Bendtsen F. Kidney injury in cirrhosis: 30. Guevara M, Gines P, Bandi JC, Gilabert R, Sort P, Jimenez W, Garcia-
pathophysiological and therapeutic aspects of hepatorenal syndromes. Pagan JC, Bosch J, Arroyo V, Rodes J. Transjugular intrahepatic
Liver Int 2014;34:1153-63. portosystemic shunt in hepatorenal syndrome: effects on renal
13. Rice JP, Skagen C, Said A. Liver transplant outcomes for patients with function and vasoactive systems. Hepatology 1998;28:416-22.
hepatorenal syndrome treated with pretransplant vasoconstrictors and 31. Testino G, Ferro C, Sumberaz A, Messa P, Morelli N, Guadagni B,
albumin. Transplantation 2011;91:1141-7. Ardizzone G, Valente U. Type-2 hepatorenal syndrome and refractory
14. Le Moine O, el Nawar A, Jagodzinski R, Bourgeois N, Adler M, ascites: role of transjugular intrahepatic portosystemic stent-shunt in
Gelin M, Cremer M. Treatment with terlipressin as a bridge to eighteen patients with advanced cirrhosis awaiting orthotopic liver
liver transplantation in a patient with hepatorenal syndrome. Acta transplantation. Hepatogastroenterology 2003;50:1753-5.
Gastroenterol Belg 1998;61:268-70. 32. Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H,
15. Gluud LL, Christensen K, Christensen E, Krag A. Terlipressin for Klehr HU, Kramer HJ, Spengler U, Schild H, Sauerbruch T. Long
hepatorenal syndrome. Cochrane Database Syst Rev 2012;9:CD005162. term outcome after transjugular intrahepatic portosystemic stent-shunt
16. Sola E, Cardenas A, Gines P. Results of pretransplant treatment of in non-transplant cirrhotics with hepatorenal syndrome: a phase II
hepatorenal syndrome with terlipressin. Curr Opin Organ Transplant study. Gut 2000;47:288-95.
2013;18:265-70. 33. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin,
Hepatoma Research ¦ Volume 3 ¦ April 12, 2017 71